Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + decitabine
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ipilimumab + decitabine is a combination therapy investigated for the treatment of relapsed or refractory myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Ipilimumab is a recombinant human monoclonal antibody that acts as an immune checkpoint inhibitor by binding to the Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4). By blocking CTLA-4, it prevents the inhibitory signal that normally downregulates T-cell activation, thereby enhancing the immune system's ability to attack tumor cells. Decitabine is a small molecule hypomethylating agent that functions as a DNA methyltransferase inhibitor. It incorporates into DNA and covalently binds to DNA methyltransferases, leading to their depletion and subsequent global DNA hypomethylation. This process can reactivate tumor suppressor genes that were silenced by hypermethylation. The combination is designed to leverage the epigenetic priming effects of decitabine to enhance the efficacy of CTLA-4 blockade in myeloid malignancies.
- Other names
- ipilimumab and decitabine
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)
Beyond the preview
Go deeper on ipilimumab + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + decitabine.